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ABSTRACT
Background: The expiration of patents of brand inhalation medications and the ongoing pressure
on healthcare budgets resulted in a growing market for generics. Aim: To study the use of brand
and generic inhalation medication and the frequency of switching between brand and generic and
between devices. In addition, we investigated whether switching affected adherence.Methods: From
dispensing data from theDutch PHARMODatabaseNetwork a cohort aged 5 years, using 1 year of
inhalation medication between 2003 and 2012 was selected. Switching was defined as changing from
brand to generic or vice versa. In addition, we studied change in aerosol delivery device type (e.g.,
DPI, pMDI, and nebulizers). Adherence was calculated using the medication possession ratio (MPR).
Results: The total cohort comprised 70,053 patients with 1,604,488 dispensations. Per calendar year,
5% switched between brand and generic inhalation medication and 5% switched between devices.
Median MPRs over the first 12 months ranged between 33 and 55%. Median MPR over the total period
was lower after switch frombrand togeneric andvice versa for formoterol (44.5 vs. 42.1 and63.5 vs. 53.8)
andbeclomethasone (93.8 vs. 59.8 and81.3 vs. 55.9).Conclusion: Per year, switchingbetweenbrand and
generic inhalation medication was limited to 5% of the patients, switching between device types was
observed in 5% as well. Adherence to both generic and brand inhalation medication was low. Effect
of switching on adherence was contradictory; depending on time period, medication and type, and
direction of switching. Further research on reasons for switching and potential impact on clinical out-
comes is warranted.
Introduction
To control healthcare costs, the Dutch health authorities
adopted a preference policy, which enabled pharmacists
to favor the dispensations of generic drugs irrespective of
the physician’s prescription [1–3]. Switching of inhalation
therapy may coincide with a change of aerosol delivery
device type as substitution is permitted if generic names
are used on the prescription [4]. In principle, the choice
of aerosol delivery device type is based on patient char-
acteristics, like age, inspiratory force, device characteris-
tics, and patient’s preference [5] and each aerosol deliv-
ery device type requires careful and repeated instruction.
Unexpected change in aerosol delivery device type may
lead to confusion and incorrect use.
In order to get generic medications licensed, proof of
clinical bioequivalence is needed. As the drug delivery
CONTACT Hettie M. Janssens h.janssens@erasmusmc.nl Institute: ErasmusMC/Sophia Children’s Hospital, Department: Pediatrics, Division of Respiratory
Medicine and Allergology, P.O. box ,  CB Rotterdam, the Netherlands.
Supplemental data for this article can be accessed at www.tandfonline.com/ijas.
and intended action of inhaled drug products for local
action, such as dry powder aerosol delivery device types
(DPIs) do not rely on the systemic circulation, the bioe-
quivalence cannot be demonstrated based on drug con-
centration in blood/plasma [6]. The European Medicines
Agency (EMA)’s “guideline on requirements for clinical
documentation of orally inhaled products for asthma and
COPD” states that for aerosol delivery device types with
the same substance and required flow rate, similar in vitro
performance is sufficient to show equivalence [7]. In vitro
performance includes particle-size distribution, fine par-
ticle fraction of emitted dose, and flow-rate dependency
tested under validated circumstances.
Healthcare professionals are concerned about switch-
ing between asthma drugs because it may negatively affect
disease control through low adherence, and incorrect use
©  M. Engelkes, J. C. van Blijverveen, J. A. Overbeek, J. G. Kuiper, R. C. M. Herings, M. C. J. M. Sturkenboom, J. C. de Jongste, K. M. C. Verhamme, and Hettie M. Janssens. Published with
license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-
ncnd/./), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built
upon in any way.
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of aerosol delivery device types [3,8]. In literature, there is
evidence that switching has a negative impact on adher-
ence and disease control through changes in color, size,
and packaging [9–12]. Data from a questionnaire study
showed that patients who switched asthma medication,
more often experienced difficulties using the device (23%
vs. 13%), were less likely to be adherent (55% vs. 68%)
and were less likely to report being asthma controlled
(69% vs. 83%) compared to patients who did not switch
[13]. pMDIs, DPIs, and nebulizers have different flow-
dependent pulmonary deposition patterns that could
account for differences in therapeutic effect, indepen-
dent of pharmacokinetics. DPIs, in particular, can vary
markedly in design and method of operation [14]. This
could lead to different handling errors in a real-life con-
text [15].When long-termusers of branded inhaled drugs
are dispensed generics delivered by a different aerosol
delivery device type, they are likely to be unfamiliar with
the new device and could become aware of a change in
taste/sensation [16]. This may reduce their confidence in
the efficacy of the generic drug, increasing the risk of poor
compliance and possibly loss of asthma control.
To assess whether the raised concerns are valid, we
investigated the frequency of use and switching between
brand and generic inhalation medication, the frequency
of switching between aerosol delivery device types and
calculated the adherence before and after switching in
real life in the Netherlands. We hypothesized that switch-
ing does occur frequently and that it might influence
adherence.
Methods
Database
We conducted a cohort study in a large population-
based patient centric network of healthcare databases (the
Dutch PHARMO Database Network, www.pharmo.nl).
This database combines data from different healthcare
settings, including general practice (GP), in- and out-
patient pharmacy and hospitals. It includes high-quality
complete information linked on a patient level, includ-
ing patient demographics, drug-dispensing records from
community pharmacies, hospital-discharge records, and
GP diagnoses of more than two million individuals
throughout the Netherlands [17]. The Out-patient Phar-
macy Database comprises detailed information on the
dispensed package, the type of prescriber, the dispensing
date, the amount dispensed, and the written dose instruc-
tions. The drugs are coded according to the Anatomical
TherapeuticChemical (ATC)Classification systemaswell
as coded by sales registry number [18]. This study was
approved by the independent compliance committee of
the PHARMO Institute.
Study population
The dynamic study population comprised all patients
aged 5 years or older, using inhalation medication for at
least 1 year during the study period. All patients were
followed from study entry (1st of January 2003 or fifth
birthday, whichever came last) until the end of the study
period (31st of December 2012 or leaving the pharmacy,
whichever occurred first).
Brand-generic cohort
From the study population, we identified all patients, who
got dispensations for inhalation medication for which
generic substitutes were available at any time between
2003 and 2012. Because of the dynamic character, the cal-
culations were done per calendar year, thus we selected
only patients with the complete calendar year of follow-
up and at least one dispensation in that specific calendar
year. The information on availability of generic substitutes
during the study period was retrieved from themedicines
information bank from the Dutch Medicines Evaluation
Board [19]. The inhalationmedications for which generic
substitutes were available included short acting beta2 ago-
nists, short acting muscarinic antagonists, inhaled corti-
costeroids (ICS), and long acting beta2 agonists (online
Table 1). If for a specific ATC code, less than 0.5% of
the received medications were generic, this ATC was not
included in the analyses.
Switch was defined as a change from brand to generic
or vice versa compared to the prior dispensing of a medi-
cation with the same ATC code in the previous 365 days,
but not necessarily in the same calendar year (online
Figure 1).
Per calendar year, we categorized patients into three
groups: patients exclusively using brand; patients exclu-
sively using generics; and patients using both generic
and brand medication in a specific calendar year (mixed
users).
Table . Baseline characteristics.
Variable
Participants (n) ,
Age, year (median) . (.–.)
Gender, % men %
Medication users
year Total (n) Adults Children
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
 , , ,
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Figure . Overview of the diﬀerent cohorts.
Device cohort
From the study population, we identified all patients who
used inhalation medication for which different devices,
per ATC code, were available between 2003 and 2012.
We classified the type of device as follows: pressurized
metered dose aerosol delivery device types (pMDIs),
DPI, or wet nebulizers. To gain more insight into switch-
ing within device category, we subclassified the DPI
into Breezhaler R©, Clickhaler R©, Cyclohaler R©, Diskus R©,
Easyhaler R©, Handihaler R©, Inhalette R©, Novolizer R©,
Rotadisk R©, and Turbuhaler R©. For the pMDIs, only
beclomethasone (ATC code R03BA02) was classified
into subclasses; Becotide R©, Becloforte R©, Extrafine R©, and
Autohaler R© (online Table 2). Unfortunately, we did not
have information in our data, which holding chamber
was used with the pMDI.
Adherence
Adherence was calculated by using the medication pos-
session ratio (MPR), which is defined as the sum of
the days for which inhalation medication was dispensed
divided by the total number of days between the first
and the last prescription plus the duration of the last
prescription, multiplied by 100 and expressed as a per-
centage. Adherence was calculated, stratified per generic,
brand, and switch. We calculated the MPR for five differ-
ent switches, namely: (1) switch fromgeneric to brand and
vice versa; (2) switching from generic to brand without
switch in aerosol delivery device type (DPI/pMDI/NEB)
and vice versa; (3) switching from generic to brand with
concurrent switch in delivery system and vice versa; (4)
switching between delivery systems; and (5) switching
between delivery systems without concurrent switch in
generic/brand switching.
Adherence before and after switching from brand and
generic and vice versa was calculated for the three main-
tenance medications for which a generic substitute was
available namely beclomethasone, budesonide, and for-
moterol. MPR was calculated for the total study period;
Figure . Proportion of users with generic only, brand only, or
mixed use of all ATC codes within the brand-generic cohort, strati-
ﬁed by calendar year.
following the first dispensation. For patients exclusively
using generic or brand, a periodMPRwas calculated in a 6
and 12 months period following the first brand or generic
dispense, to exclude occasional use.
For patients with switching, MPR calculations were
restricted to patientswith at least twodispensations before
and after switching and to the same patients before and
after switch to control for patient characteristics. The
MPR was calculated for the total study period before and
after switching, and in the 6 and 12 months before and
after the switch date. We excluded the switch dispensa-
tion from this analysis as this would introduce differen-
tial overestimation of adherence in patients who switched.
In case of multiple switching the follow-up time was cen-
sored at the next switch (online Figure 2).
Statistical methods
Descriptive statistics were used where numbers are pro-
vided by counts and percentages. For continuous vari-
ables, we provided medians and interquartile ranges
(IQRs). To describe the use of generic and brand medi-
cation, we divided the number of users with only generic,
or only brand, ormixed dispensations by the total number
of users per calendar year. The prevalence of dispensing
was calculated as percentage of users per calendar year,
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per ATC code and per device.We stratified by gender, fre-
quency of use (one to three vs. more than four dispensa-
tions per year) and age (5–18 vs. 18 year). To compare
adherence before and after switch, we tested MPR differ-
ences by paired measurements with the Wilcoxon signed
rank test. We considered a p value < 0.05 as statistically
significant. All analyses were performed in SPSS version
21, SPSS Inc. Chicago.
Results
The total study population included 70,052 patients with
a total of 1,604,488 dispensations of inhalation med-
ication. Median age at cohort entry was 44.5 years
(IQR 25.5–59.7), and 47% were men. At cohort entry
13,365 (19%) were children <18 years old (Table 1). An
overview of the cohorts is shown in Figure 1.
Patients were included only once, users were counted
each time when they used medication per calendar year.
Brand-generic switching
The brand-generic cohort, defined to estimate the preva-
lence of switching from brand to generic drugs and vice
versa, included 634,176 dispensations of inhalation med-
ication for which a generic substitute was available. Of
these, 188,845 (35.1%) were generic. The proportion of
generic users increased from 18% in 2003 to 31% in
2012. The generic dispensing rate was the highest for
beclomethasone, 59%of the total beclomethasone dispen-
sations from 2003 to 2012 were generic (online Figure 3).
On average 10% of the patients in the study cohort
used both generic and brand drugs in 1 calendar year
(Figure 2).
Switching between brand and generic (or vice versa)
within the same ATC code was observed in 5% of the
brand generic cohort per year, and remained stable over
time (Figure 3).
Figure . Patients with  switch (within the same ATC code) per
calendar year. s= switch from brand to generic; s= switch from
generic to brand; and total= s+ s.
Figure . Proportion of users per device per calendar, (a) children
and (b) adults.
The proportion of switching per ATC code was high-
est in salbutamol; 6% of the salbutamol users switched
in the study period (online Figure 4). The proportion of
generic salbutamol increased from 29 to 39%. All results
were similar when stratified by frequency of use or by age
(data not shown).
Notably, the switching percentage in beclomethasone
(R03BA01) was highest in 2003 and 2004, both from
brand to generic as from generic to brand, but dropped
from 2005 onward (online Figure 5).
Device switching
For patients within the device cohort (n = 338,140),
the use of pMDI, DPI, and wet nebulizers is shown in
Figure 4. In children, most dispensations were pMDIs
(49%), while in adults, DPIs were dispensed most fre-
quently (73%).
On average 16% of the adult users in the device cohort
used more than one kind of aerosol delivery device type
per calendar year, in children this was 9%. On average
2% of users in the device cohort switched from device
(within the same ATC) within 1 calendar year between
2003 and 2012. In adults, switching increased over time,
with most switches from DPI to pMDI, while children
switched mostly from pMDI to DPI.
Amongst the 161,672 users of DPI (n = 47,532
patients), on average 3% switched between devices
of the same ATC code per year. Eight percent of the
users in the beclomethasone pMDI device subcohort
(users = 8,895) switched between different
beclomethasone pMDIs. In 2003 and 2004, switching
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from becotide and becloforte to generic beclometha-
sone was most frequent. In September 2002, generic
beclomethasone was licensed into the Dutch market,
soon thereafter Becotide R© and Becloforte R© were off
license.
Medication possession ratio
The mean MPR was low for budesonide, beclometha-
sone, and formoterol, the three maintenance inhala-
tion medications for which generic substitute was avail-
able (Table 2). The median MPR (IQR) for the first
12 months following the first dispensation since study
start for patients exclusively on brand was 55% (41–82)
for budesonide, 48% (27–69) for beclomethasone, and
33% (23–49) for formoterol. The median MPR (IQR)
for the first 12 months following the first dispensation
for patients exclusively on generic was 55% (41.1–82.2)
for budesonide, 33% (16.4–57.0) for beclomethasone, and
33% (21.9–49.32) for formoterol. Patients (n = 102) who
switched from brand to generic beclomethasone were
more adherent in the first 12months after switching com-
pared to 12 months before switching (median MPR 55%
(IQR 27–82) versus 41% (IQR 27–61) (Wilcoxon signed
rank test p = 0.015). Also, patients who switched from
brand to generic budesonide (n = 77) were more adher-
ent to budesonide in the first 12 months after switching
compared to 12 months before switching (median MPR
59% (IQR 41–97) vs. 51% IQR (38–79), p = 0.015).
In contrast, adherence for switching from brand to
generic without concurrent switch of device type was
lower after switch for beclomethasone and formoterol
users.
Sensitivity analyses of the above calculations for
6 months showed comparable results. Incident users
(= defined as <365 days use of the specific ATC-code
since study start) and stratification per age group or per
gender, and concurrent switching between generic and
brand with device switch, were too low for analysis.
Discussion
In this study, we provide population level data on the
use of generic and brand inhalation medication and the
frequency of switching between brand and generic, and
between inhalation devices during a 10-year period from
2003 to 2012. In addition, we investigatedwhether switch-
ing was associated with changes in adherence. Five per-
cent of patients had one or more switches between brand
and generic per year and 16% used more than one device.
Adherence was low, and hardly affected by switching.
Our results provide evidence that in the study period
many patients continued to use brandmedication, but use
of generics tended to increase overtime.
This increase is in line with the trend in recent years
shown by data from theDutch Foundation of Pharmaceu-
tical statistics where the proportion of generic medicines
among the total number of prescription medicines dis-
pensed by pharmacies increased to 70% in 2013. Yet
generic medicines accounted for just 16% of the costs of
all medicines [20]. However, when evaluating the poten-
tial cost benefits of switching aerosol delivery device
types, all relevant costs should be considered, includ-
ing those arising from additional consultations, the time
required for training and the management of any subse-
quent acute events [21]. This would be the scope for a next
study.
For some drugs, e.g., beclomethasone, there was a
marked switch from generic to brand. This was already
observed by Fraser et al. [22]. In our study, the use of
brand beclomethasone increased when beclomethasone
pMDI with ultrafine particles (Qvar R©) was introduced
to the market [23]. Extra caution is needed when Qvar
is switched to generic beclomethasone pMDI, as generic
beclomethasone particles are much larger than those of
Qvar (3.5 vs. 1.1 um), which requires adjustment of dose
and may affect efficacy [24–26].
In line with previous research [27], adherence to both
generic and brand inhalation medication within the first
12 months following the first dispensation was low for
beclomethasone, formoterol, and budesonide with MPR
ranging between 40 and 55%. In principle, adherence is
considered good in case theMPR 80%. From adherence
studies on chronicmedication, it is known that adherence
is the highest upon treatment initiation, but decreases
rapidly in the first 3–6months [28–30]. MPR calculations
and fixed time periods are not ideal to calculate adher-
ence; however, it is a common method used in database
studies to estimate drug use [31].Differences in adherence
before and after switch were observed in users of budes-
onide and beclomethasone, where the median MPR was
different after switch, direction depending on the time
period, type of medication, and type of switch. The num-
bers were, however, low.
The low use of ICS was also observed in a study in
the United States by Fung et al. They studied the effect
of generic only drug benefits on patients use of ICS in
an elderly population, Patients reduced their already low
ICS use in response to losing drug coverage. The clinical
effect of these drug use changes was not analyzed in this
study [32].
Studies from New Zealand on switching between Ven-
tolin and salbutamol use in patients with asthma, contra-
dictory results on the effectiveness of generic versus brand
name drugs [33–35].
In line with our study, a retrospective study by Thomas
et al. in the United Kingdom observed that most switches
were from DPIs to pMDIs [36].
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In the Netherlands, the provision of generic medicines
and pharmacy services in the Dutch healthcare system
has undergone substantial changes in 2008. A num-
ber of insurance companies initiated a policy of selec-
tive contracting of generic medicines; as of the 1st of
July 2008, these insurers reimburse only the cheapest
generic product within a number of big-selling therapeu-
tic classes [37]. However, generic substitution coincides
with increased responsibilities of Dutch pharmacists on
educating patients about the reasons for generic substi-
tution, the benefits of adherent drug use and correct use
of inhalation device [38]. Patient education increases the
acceptance of use of generic drugs [12]. This is under-
lined by a recent review that showed nonadherence to
therapy and incorrect aerosol delivery device type usage
are recognized as major factors in poorly or uncon-
trolled asthma and Chronic Obstructive Pulmonary Dis-
ease (COPD) and switching patients to a different aerosol
delivery device type device may exacerbate these prob-
lems, particularly in patients who disagree to switch. The
authors conclude that where switching is permitted or
mandatory, adequate patient instruction and follow-up
monitoring should be provided routinely [4].
This is an observational study using a pharmacy
database as primary data source. This brings some limi-
tations. Dispensing of a medicine does not equate actual
use, nor guarantees a good inhalation technique. Our
database could not be used to investigate the reasons for
switching as there was no link to clinical data nor to type
of holding chamber. Also health insurance data were lack-
ing, while a recent review in the United States concluded
that higher out-of-pocket costs for patients, depending
on their health insurance, have consistently been asso-
ciated with lower rates of long-term medication adher-
ence [39]. We observed a relatively low percentage of
switching from brand to generic during our study period
2003–2012. Since 2012, new generic asthma drugs came
on the market and switching might be higher in datasets
with more recent data [13]. Unfortunately, at the time of
the study we did not have access to data after 2012.
Note that better or worse adherence for inhalation
medication does not automatically imply better disease
control.MPR does not tell whether inhalationmedication
was taken correctly. Inhalation technique is important for
efficient aerosol delivery into the lungs, and therefore for
efficacy of the drug.
Conclusion
Generic dispensing in the Netherlands is increasing.
Patients on inhalation medication, both generics and
brands, have low adherence rates. We did not observe
a clear impact of switching on adherence rates, which
is reassuring. Effect of switching on adherence was
contradictory, depending on the time period, the med-
ication and the type, and direction of switching. How-
ever, with more generic drugs coming on the market, the
chance of switchingmay become higher. Further research
on reasons for switching and the potential impact on clin-
ical outcomes is warranted.
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